Skip to content
UK AML Research Network
Search field required
Patient & Public
  • Clinical Trials
    • Newly Diagnosed
    • Relapse/Refractory
    • Transplant Related
    • Supportive Care
  • MyeCare Registry
  • Clinical Resources
    • Guidelines & Clinical Resources
    • National High Risk & Relapsed AML MDT
    • Approved UK AML Treatments
  • Education & Training
    • Notable Recent Papers
    • Upcoming Meetings & Opportunities for Junior Colleagues
    • AML Bites Journal Club Program
  • Research
    • Clinical Research Opportunities
    • Translational Research
    • Data Collection Projects
  • About
  • Contact
UK AML Research Network
  • Clinical Trials
    • Newly Diagnosed
    • Relapse/Refractory
    • Transplant Related
    • Supportive Care
  • MyeCare Registry
  • Clinical Resources
    • Guidelines & Clinical Resources
    • National High Risk & Relapsed AML MDT
    • Approved UK AML Treatments
  • Education & Training
    • Notable Recent Papers
    • Upcoming Meetings & Opportunities for Junior Colleagues
    • AML Bites Journal Club Program
  • Research
    • Clinical Research Opportunities
    • Translational Research
    • Data Collection Projects
  • About
  • Contact
Search field required
Patient & Public

Treatment Information

Intensive chemotherapy

DA (Daunorubicin and cytarabine)

DA + Mylotarg (Gemtuzumab ozogamicin (Mylotarg) with daunorubicin and cytarabine)

DA + Midostaurin

DA + Quizartinib

Liposomal cytarabine-daunorubicin (Vyxeos)

FLAG-Ida

HiDaC (High dose cytarabine)

Less intensive and targeted therapies

Venetoclax and azacitidine

Venetoclax and low dose cytarabine

Ivosidenib and azacitidine

Gilteritinib

Azacitidine injections (Vidaza)

LDAC (Low dose cytarabine)

Hydroxyurea

Maintenance therapies

Oral azacitidine tablets (Onureg)

Sorafenib

Stem cell or bone marrow transplants

CRUK information on stem cell transplant

Anthony Nolan information on stem cell transplant

© 2026 UK AML Research Network

  • Cookie Policy
  • Privacy Policy and Terms of Use

Powered by The Communications Group